Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1A/B Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours

NCT02521844 is registered in ClinicalTrials.gov with EDDC (Experimental Drug Development Centre), A*STAR Research Entities as lead sponsor.

NCT NCT02521844
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02521844 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1A/B Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours
Lead sponsor
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 31, 2015
Completion date
October 31, 2024
Enrollment
89 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors